An Innovative Delivery System of Oxygen-Releasing Nanospheres and Self-Healing Hydrogels Enhances the Therapeutic Effectiveness of Bone Marrow Mesenchymal Stem Cells for Chronic Limb-Threatening Ischemia.

Purpose: Bone marrow mesenchymal stem cells (BMSCs) have emerged as promising candidate for postoperative therapeutics in chronic limb-threatening ischemia (CLTI). Nevertheless, their effectiveness is limited by their low survival rate and impaired functionality in the ischemic microenvironment. To overcome these challenges, we have devised an innovative delivery approach to support the utilization of BMSCs in CLTI therapy.

β-Ketoenamine covalent organic framework nanoplatform combined with immune checkpoint blockade via photodynamic immunotherapy inhibit glioblastoma progression.

The synergistic approach of combining photodynamic immunotherapy with endogenous clearance of PD-L1 immune checkpoint blockade therapy holds promise for enhancing survival outcomes in glioblastoma (GBM) patients. The observed upregulation of O-GlcNAc glycolysis in tumors may contribute to the stabilization of endogenous PD-L1 protein, facilitating tumor immune evasion. This study presents a pH-adapted excited state intramolecular proton transfer (ESIPT)-isomerized β-ketoamide-based covalent organic framework (COF) nanoplatform (denoted as OT@COF-RVG).

Treatment planning for very high energy electrons: Studies that indicate the potential of the modality.

Background And Purpose: Radiotherapy using Very High Energy Electrons (VHEE) has the potential to reduce dose to organs at risk compared to photons. This article therefore reviews treatment planning for VHEE, to clarify the potential benefit of the modality.

Materials And Methods: Articles on VHEE were identified and those which focused on treatment planning were manually selected, particularly those which contained results on patient datasets.

Assessing the Performance of ChatGPT in Answering Patients' Questions Regarding Congenital Bicuspid Aortic Valve.

Aim: Artificial intelligence (AI) models, such as ChatGPT, are widely being used in academia as well as by the common public. In the field of medicine, the information obtained by the professionals as well as by the patients from the AI tools has significant advantages while at the same time posing valid concerns regarding the validity and adequacy of information regarding healthcare delivery and utilization. Therefore, it is important to vet these AI tools through the prism of practicing physicians.

Aptamer sgc8-Modified PAMAM Nanoparticles for Targeted siRNA Delivery to Inhibit BCL11B in T-Cell Acute Lymphoblastic Leukemia.

Introduction: T-cell acute lymphoblastic leukemia (T-ALL) is a malignant hematological disease with limited targeted therapy options. Overexpression of B-cell lymphoma/leukemia 11B is frequently observed in T-ALL and contributes to leukemogenesis. Knockdown of BCL11B inhibits T-ALL cell proliferation and induces apoptosis, making it a potential therapeutic target.

Co-delivery of vitamin and amino acid within MOFs for oxidative stress-based tumor gas therapy.

As an alternative to chemotherapy, emerging gas therapy is considered a "green" treatment due to its minimal side effects. However, even typical gas molecules like nitric oxide (NO) face challenges such as a very short half-life (1.5-6 min), poor targeting, and limited therapeutic effects.

Efficacy and tolerability of celastrol and edaravone in the multiple-hit rat model of infantile spasms.

Objective: To test whether anti-inflammatory and antioxidant drugs that inhibit the nuclear factor kappa light chain enhancer of activated B cells (NF-kB), celastrol and edaravone, suppress spasms and improve developmental outcomes in the multiple-hit rat model of refractory infantile spasms (IS) due to structural lesions.

Methods: Postnatal day 3 (PN3) Sprague-Dawley rats were treated according to the multiple-hit IS model protocol. Using a randomized, blinded, vehicle-controlled, dose- and time-response study design, we tested the effects of single celastrol [1, 2, or 4 mg/kg intraperitoneally (i.

Controlled Delivery of Paclitaxel via Stable Synthetic Protein Nanoparticles.

Despite decades of intense research, glioma remains a disease for which no adequate clinical treatment exists. Given the ongoing therapeutic failures of conventional treatment approaches, nanomedicine may offer alternative options because it can increase the bioavailability of drugs and alter their pharmacokinetics. Here, a new type of synthetic protein nanoparticles (SPNPs) is reported that allow for effective loading and controlled release of the potent cancer drug, paclitaxel (PTX) - a drug that so far has been unsuccessful in glioma treatment due to hydrophobicity, low solubility, and associated delivery challenges.